Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
ONLS
АТХ:H.05.B.X Other antiparatyroid drugs
H.05.B.X.02 Paricalcitol
Pharmacodynamics:The synthetic analogue of calcitriol regulates the exchange of calcium and phosphorus. Interacts with the vitamin receptors, selectively activating the vitamin-mediated response. Reduces the level of parathyroid hormone, inhibiting its synthesis and secretion.
Activation of calcitriol receptors promotes normalization of the process of bone tissue formation.
Pharmacokinetics:After intravenous bolus administration, the maximum concentration in the blood plasma rapidly decreases within 2 hours, then - decreases linearly. The connection with plasma proteins is 99%.
Therapeutic effect develops after the reception. Metabolism in the liver.
Half-life is 5-7 hours Elimination with feces (63%) and kidneys (17%).
Indications:It is used to treat and prevent secondary hyperparathyroidism due to chronic renal failure.
IV.E20-E35.E21.1 Secondary hyperparathyroidism, not elsewhere classified
XIV.N25-N29.N25.8 Other disorders due to renal tubular dysfunction
Contraindications:Hypervitaminosis, individual intolerance.
Carefully:Simultaneous use with cardiac glycosides.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Intravenously through a hemodialysis catheter, or slowly for 30 seconds.
The dose is selected individually, according to a special scheme that takes into account the body weight and the level of parathyroid hormone.
Side effects:Central and peripheral nervous system: headache, dizziness.
Respiratory system: pneumonia.
The cardiovascular system: tachycardia.
Digestive system: gastrointestinal bleeding, dry mouth, dyspeptic disorders, perversion of taste.
Allergic reactions.
Overdose:Increased side effects.
Treatment is symptomatic.
Interaction:Enhances the toxic effects of cardiac glycosides.
With simultaneous use with ketoconazole, the concentration of paricylcitol in the blood plasma increases.
Special instructions:Excessive suppression of the synthesis of parathyroid hormone can lead to a decrease in metabolic processes in bone and cartilaginous tissue.In the treatment of paricalcitol, continuous monitoring of the hormone content and calcium in the blood plasma for the purpose of timely correction of the dose of the drug.